West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced Eric M. Green, President and CEO, will assume the additional responsibility of Chair of the Company’s Board of Directors, effective as of West’s next Annual Shareholders’ Meeting, which is expected to be May 24, 2022. Mr. Green will succeed Patrick Zenner, who will retire from the Company’s Board at that time.
“Eric has successfully led the company since 2015, while advancing the Company’s mission and increasing shareholder value,” said Patrick Zenner, Chair of the Board, West. “I am confident that Eric will lead the Board with the collaborative style and strategic, operating mindset demonstrated over his tenure as CEO. He has effectively navigated the organization to meet the ongoing challenges of the pandemic while advancing the focus on innovative, high-quality products and solutions to meet customer demand. Moreover, he continues to pursue sustainable and responsible business practices that serve all our stakeholders in the healthcare industry.”
In addition to Mr. Green’s appointment, West has also announced that Paolo Pucci will serve as the Lead Independent Director for the Board, effective at the 2022 Annual Shareholders’ Meeting. Aligned to West’s corporate governance principles, when the Chair and role of CEO are combined, the Board will appoint a Lead Independent Director. Mr. Pucci will be the primary liaison between Mr. Green and the Board with ability to call and lead independent sessions with the Board.
“Pat has been an instrumental member of our Board of Directors for the past 20 years and in that time has been an outstanding leader, visionary and champion for West and our communities across the globe,” commented Eric M. Green, President and CEO. “We would like to extend our appreciation to Pat for his long-standing commitment and unrelenting dedication as Chair to our Board and West. At the same time, I congratulate Paolo on his new role as I am honored to extend my executive responsibilities and serve as Chair of the Board of Directors.”